TRUE Private Wealth Advisors Invests $351,000 in Novo Nordisk A/S $NVO

TRUE Private Wealth Advisors bought a new position in shares of Novo Nordisk A/S (NYSE:NVO) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 5,080 shares of the company’s stock, valued at approximately $351,000.

Other hedge funds have also added to or reduced their stakes in the company. Stone House Investment Management LLC bought a new stake in Novo Nordisk A/S during the 1st quarter worth about $30,000. NewSquare Capital LLC increased its position in shares of Novo Nordisk A/S by 174.1% in the second quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock valued at $31,000 after acquiring an additional 282 shares during the last quarter. Disciplina Capital Management LLC increased its position in shares of Novo Nordisk A/S by 162.3% in the first quarter. Disciplina Capital Management LLC now owns 480 shares of the company’s stock valued at $33,000 after acquiring an additional 297 shares during the last quarter. Dagco Inc. bought a new stake in Novo Nordisk A/S during the first quarter worth about $35,000. Finally, Mid American Wealth Advisory Group Inc. acquired a new position in Novo Nordisk A/S during the second quarter valued at approximately $37,000. Institutional investors own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms have weighed in on NVO. UBS Group lowered Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a research report on Tuesday, August 5th. TD Cowen dropped their price target on shares of Novo Nordisk A/S from $105.00 to $70.00 and set a “buy” rating on the stock in a research report on Tuesday, August 19th. BNP Paribas raised shares of Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a research report on Wednesday, August 13th. Rothschild Redb raised shares of Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 16th. Finally, Sanford C. Bernstein upgraded Novo Nordisk A/S from a “market perform” rating to an “outperform” rating in a report on Tuesday, September 9th. Two equities research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, nine have assigned a Hold rating and three have given a Sell rating to the company. According to MarketBeat, Novo Nordisk A/S currently has an average rating of “Hold” and an average price target of $59.20.

Novo Nordisk A/S Price Performance

Shares of NVO opened at $49.07 on Thursday. The firm has a market capitalization of $219.08 billion, a PE ratio of 13.48, a PEG ratio of 2.33 and a beta of 0.65. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56. The company’s 50-day moving average is $54.20 and its 200-day moving average is $60.61. Novo Nordisk A/S has a fifty-two week low of $45.05 and a fifty-two week high of $112.52.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $1.02 EPS for the quarter, beating analysts’ consensus estimates of $0.77 by $0.25. The business had revenue of $11.74 billion for the quarter, compared to analyst estimates of $11.98 billion. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. Novo Nordisk A/S has set its FY 2025 guidance at EPS. Equities analysts forecast that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.